In patients with diabetes^ how do the long-acting insulin analogues (LAIA) (e.g. glargine and detemir) compare to NPH?
Compared to NPH insulin^ LAIAs have no advantage in A1c^ no evidence for hard outcomes^ and no difference in severe hypoglycemia. The small reductions in other hypoglycemic symptoms have a high risk of bias. Patients with significant hypoglycemia from NPH should consider using lower NPH doses first. If NPH dosage reduction doesn’t resolve hypoglycemic episodes^ patients and clinicians may consider LAIAs.
*** Original Documents can be found and downloaded using the link provided below ***
Publication Date: 2013-12-5
Last Updated on PCR: 2017-03-31 16:50:49